and psychiatric problems. Recent studies demonstrated that transplantation of all kinds of human stem cells into patients with PD could help replacing endogenous degenerating dopamine (DA) neurons and ameliorate the clinical symptoms of PD (2, 6, 7).Recent studies have revealed the successful reversal of parkinsonian symptoms in monkeys, rats, and patients with PD after transplantation of different kinds of stem cells (18,22,23,24). However, the safety and valuation of transplantation of neural precursor cells (NPCs) remains controversial.A boy with ataxia telangiectasia (AT) was treated not only with intracerebellar but intrathecal injection of human fetal NPCs. Four years after the transplantation he came with a multifocal brain tumor. Molecular and cytogenetic genetics detectionsParkinson's disease (PD), also called parkinsonism, is the most common central nervous system degenerative disease secondary to dopaminergic neuron loss in the substantia nigra pars compacta (SNc), decrease in the synthesis of dopamine and excitation of acetylcholine (24). Most evident symptoms are movement-related, including movement disorders, tremor and rigidity.Gradually, thinking and behavioral problems may arise, with dementia commonly occurring in the last phases of the disease, whereas depression is the most common psychiatric symptom.Dementia and depression will heavily influence the quality of patient lives. Other symptoms include sensory, emotional AIM: The aim of this study was to evaluate the clinical safety, feasibility and efficacy of transplantation of neural precursor cells (NPCs) in the treatment for Parkinson's disease (PD).
MATERIAL and METHODS:Twenty-one patients, aged 42-79 years (median age 57.33 years), participated in the study. A total of 3 × 107 NPCs in 0.25 ml were deposited unilaterally into the striatum. To access the effectiveness of first transplantation surgery, comparisons between the resulting pre-first surgery evaluation and pre-second surgery evaluation were made with repeatedmeasures analysis of variance. Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn-Yahr, PDQ-39 and Schwab-England Scores were used to evaluate the Parkinson patients' neurofunctions. Four aspects were used to assess the possible side effects of transplantation: a) tumor formation, b) immune rejection and use of immunosuppressant, c) graft induced complication and d) delivery related side effects.
RESULTS:This study demonstrated that the symptoms of PD patients were statistically improved after transplantation (P<0.01). There were no obvious side effects of transplantation.
CONCLUSION:Transplantation of neural precursor cells may be a valid and safe treatment method for Parkinson's Disease.